Model for End-Stage Liver Disease Score Predicts the Mortality of Patients with Coronary Heart Disease Who Underwent Percutaneous Coronary Intervention
Table 2
Outcome comparison between groups.
Outcomes
MELD1 (n = 1342)
MELD2 (n = 1341)
MELD3 (n = 1349)
MELD4 (n = 1341)
χ2
ACM, n (%)
55 (4.1)
66 (4.9)
65 (4.8)
87 (6.5)
8.452
0.038
CM, n (%)
42 (3.1)
51 (3.8)
53 (3.9)
72 (5.4)
9.175
0.027
MACCE, n (%)
172 (12.8)
189 (14.1)
194 (14.4)
209 (15.6)
4.262
0.234
MACE, n (%)
159 (11.8)
172 (12.8)
178 (13.2)
185 (13.8)
2.386
0.496
Heart failure, n (%)
44 (3.3)
43 (3.2)
38 (2.8)
38 (2.8)
0.808
0.848
Bleeding events, n (%)
41 (3.1)
29 (2.2)
43 (3.2)
46 (3.4)
4.288
0.232
Readmission, n (%)
175 (13.0)
184 (13.7)
182 (13.5)
196 (14.6)
1.493
0.684
TVR, n (%)
67 (5.0)
67 (5.0)
82 (6.1)
66 (4.9)
2.505
0.474
MELD, model for end-stage liver disease; ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular event; MACCE, major adverse cardiovascular and cerebrovascular event; TVR, target vessel reconstruction.
